Literature DB >> 33674853

The past, present, and future management of brain metastases in EGFR-mutant non-small cell lung cancer.

Paul W Sperduto1, Emil Lou2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33674853      PMCID： PMC8168810          DOI： 10.1093/neuonc/noab054

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  10 in total

1.  Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

Authors:  Hussein A Tawbi; Peter A Forsyth; Alain Algazi; Omid Hamid; F Stephen Hodi; Stergios J Moschos; Nikhil I Khushalani; Karl Lewis; Christopher D Lao; Michael A Postow; Michael B Atkins; Marc S Ernstoff; David A Reardon; Igor Puzanov; Ragini R Kudchadkar; Reena P Thomas; Ahmad Tarhini; Anna C Pavlick; Joel Jiang; Alexandre Avila; Sheena Demelo; Kim Margolin
Journal:  N Engl J Med       Date:  2018-08-23       Impact factor: 91.245

2.  Prognostic Value of Exon 19 Versus 21 EGFR Mutations Varies According to Disease Stage in Surgically Resected Non-small Cell Lung Cancer Adenocarcinoma.

Authors:  Stéphane Renaud; Joseph Seitlinger; Francesco Guerrera; Jérémie Reeb; Michèle Beau-Faller; Anne-Claire Voegeli; Joelle Siat; Christelle Clément-Duchêne; Angelica Tiotiu; Nicola Santelmo; Lorena Costardi; Enrico Ruffini; Pierre-Emmanuel Falcoz; Jean-Michel Vignaud; Gilbert Massard
Journal:  Ann Surg Oncol       Date:  2018-01-23       Impact factor: 5.344

3.  Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.

Authors:  Emmet J Jordan; Hyunjae R Kim; Maria E Arcila; David Barron; Debyani Chakravarty; JianJiong Gao; Matthew T Chang; Andy Ni; Ritika Kundra; Philip Jonsson; Gowtham Jayakumaran; Sizhi Paul Gao; Hannah C Johnsen; Aphrothiti J Hanrahan; Ahmet Zehir; Natasha Rekhtman; Michelle S Ginsberg; Bob T Li; Helena A Yu; Paul K Paik; Alexander Drilon; Matthew D Hellmann; Dalicia N Reales; Ryma Benayed; Valerie W Rusch; Mark G Kris; Jamie E Chaft; José Baselga; Barry S Taylor; Nikolaus Schultz; Charles M Rudin; David M Hyman; Michael F Berger; David B Solit; Marc Ladanyi; Gregory J Riely
Journal:  Cancer Discov       Date:  2017-03-23       Impact factor: 39.397

4.  Impact of Sequencing Radiation Therapy and Immune Checkpoint Inhibitors in the Treatment of Melanoma Brain Metastases.

Authors:  Daniel A Pomeranz Krummel; Tahseen H Nasti; Benjamin Izar; Robert H Press; Maxwell Xu; Lindsey Lowder; Laura Kallay; Manali Rupji; Havi Rosen; Jing Su; Walter Curran; Jeffrey Olson; Brent Weinberg; Matthew Schniederjan; Stewart Neill; David Lawson; Jeanne Kowalski; Mohammad K Khan; Soma Sengupta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-02-11       Impact factor: 7.038

5.  Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

Authors:  Vincent A Miller; Vera Hirsh; Jacques Cadranel; Yuh-Min Chen; Keunchil Park; Sang-We Kim; Caicun Zhou; Wu-Chou Su; Mengzhao Wang; Yan Sun; Dae Seog Heo; Lucio Crino; Eng-Huat Tan; Tsu-Yi Chao; Mehdi Shahidi; Xiuyu Julie Cong; Robert M Lorence; James Chih-Hsin Yang
Journal:  Lancet Oncol       Date:  2012-03-26       Impact factor: 41.316

6.  Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.

Authors:  Teppei Nishii; Tomoyuki Yokose; Yohei Miyagi; Yataro Daigo; Tetsuya Isaka; Hideyuki Furumoto; Hiroyuki Ito; Shuji Murakami; Tetsuro Kondo; Haruhiro Saito; Fumihiro Oshita; Kouzo Yamada; Shoichi Matsukuma; Haruhiko Nakayama; Munetaka Masuda
Journal:  Asia Pac J Clin Oncol       Date:  2016-06-28       Impact factor: 2.601

7.  Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial.

Authors:  Zhenzhou Yang; Yan Zhang; Rongqing Li; Abulimiti Yisikandaer; Biyong Ren; Jianguo Sun; Jianjun Li; Long Chen; Ren Zhao; Juying Zhang; Xuefeng Xia; Zhongxing Liao; David P Carbone
Journal:  Neuro Oncol       Date:  2021-06-01       Impact factor: 12.300

8.  Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiation.

Authors:  Oscar Arrieta; Cynthia Villarreal-Garza; Jesús Zamora; Mónika Blake-Cerda; María D de la Mata; Diego G Zavala; Saé Muñiz-Hernández; Jaime de la Garza
Journal:  Radiat Oncol       Date:  2011-11-25       Impact factor: 3.481

9.  Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.

Authors:  Yi-Long Wu; Masahiro Tsuboi; Jie He; Thomas John; Christian Grohe; Margarita Majem; Jonathan W Goldman; Konstantin Laktionov; Sang-We Kim; Terufumi Kato; Huu-Vinh Vu; Shun Lu; Kye-Young Lee; Charuwan Akewanlop; Chong-Jen Yu; Filippo de Marinis; Laura Bonanno; Manuel Domine; Frances A Shepherd; Lingmin Zeng; Rachel Hodge; Ajlan Atasoy; Yuri Rukazenkov; Roy S Herbst
Journal:  N Engl J Med       Date:  2020-09-19       Impact factor: 91.245

10.  Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival.

Authors:  Karmen Stanic; Matjaz Zwitter; Nina Turnsek Hitij; Izidor Kern; Aleksander Sadikov; Tanja Cufer
Journal:  Radiol Oncol       Date:  2014-04-25       Impact factor: 2.991
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.